HLA-DP4 ͉ peptide epitope ͉ tumor recognition ͉ vaccine T here is increasing evidence that the immune system has the ability to recognize tumor-associated antigens expressed in human malignancies and to induce antigen-specific humoral and cellular immune responses to these targets. In epithelial ovarian cancer (EOC), support for the role of immune surveillance of tumors comes from our recent observation indicating that the presence of intraepithelial CD8
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here is increasing evidence that the immune system has the ability to recognize tumor-associated antigens expressed in human malignancies and to induce antigen-specific humoral and cellular immune responses to these targets. In epithelial ovarian cancer (EOC), support for the role of immune surveillance of tumors comes from our recent observation indicating that the presence of intraepithelial CD8
ϩ -infiltrating T lymphocytes in tumors is associated with improved survival of patients with the disease (1) . Although the majority of women with advanced-stage ovarian cancer respond to first-line chemotherapy, most of these responses are not durable, and Ͼ70% of patients die of recurrent disease within 5 years of diagnosis. Therefore, the development of strategies to enhance the potential of tumor antigen-specific CD8 ϩ T and CD4 ϩ T cells is urgently needed for extending remission rates in this disease. In this regard, cancer-testis antigens, a unique class of antigens that demonstrate high levels of expression in adult male germ cells but generally not in other normal adult tissues and aberrant expression in a variable proportion of a wide range of different cancer types, are promising candidates for immunotherapy. Among cancer-testis antigens, NY-ESO-1 (2) is one of the most spontaneously immunogenic tumor antigens described so far. Previously, we reported that NY-ESO-1 is a promising target for specific immunotherapy of EOC (3) .
Although the majority of cancer vaccine trials have focused on eliciting antigen-specific CD8 ϩ T cells, a growing body of evidence indicates that CD4 ϩ T cells play a pivotal role in orchestrating these responses. The multiple roles of antigen-specific CD4 ϩ T cells include the provision of help to CD8 ϩ T cells during the primary and secondary immune responses, direct cytolysis, and activation of B cells for production of tumor antigen-specific Abs. Therefore, we have focused on the NY-ESO-1 epitope, ESO 157-170 , a naturally processed helper epitope that is recognized by CD4 ϩ T cells in the context of HLA-DPB1*0401 and *0402 (4), prevalent MHC class II alleles present in Ϸ43-70% of Caucasians. Moreover, the NY-ESO-1 HLA-DP4 epitope has HLA-A2 (ESO 157-165 ) (5) and HLA-A24 (ESO 158-166 ) (6) motifs embedded in its natural sequence. In this study, we evaluated whether active immunization with ESO 157-170 would elicit NY-ESO-1-specific CD4 ϩ and CD8 ϩ T cell responses in ovarian cancer patients with minimal disease burden. In addition, we characterized NY-ESO-1-specific CD8 ϩ and CD4 ϩ T cell receptor (TCR) repertoires in conjunction with functional analysis of vaccine-elicited T cell clones.
Vaccination with NY-ESO-1157-170 in Combination with Incomplete
Freund's Adjuvant (IFA) Generates Anti-NY-ESO-1 Abs. Three patients (nos. 3, 12, and 17) were baseline seropositive for anti-NY-ESO-1 Ab, and all three remained seropositive during the course of immunization (Fig. 1) . Ab titers for patient 3 increased from 1:360 at baseline to a peak of 1:2,000; Ab titers for patient 17 increased from 1:4,500 to 1:15,000 with immunization; and patient 12 became seronegative 1 year after completing immunization. Two baseline seronegative patients converted to seropositive during the course of immunization. Patient 10 became seropositive on day 274 (after 11 vaccinations) with a titer of 1:1,500 and peaking at 1:4,500 after 14 immunizations. Patient 13 became seropositive on day 169 (after 7 vaccinations) with a titer of 1:380, increasing to a titer of 1:31,108 after 11 immunizations. The patient also became seropositive for LAGE-1 on day 211 (1:1,228), increasing to 1:15,873 on day 274 (Fig. 1) . Serological responses to unrelated recombinant proteins MAGE-1, -3, -4, and -10 were used as internal controls. Although patient 16 was seropositive for MAGE-1 at baseline, there was no increase in Ab titer during the course of NY-ESO-1 immunization. However, the patient developed weakly detectable Ab to LAGE-1 long after completion of vaccine therapy (Fig. 1) .
Vaccination with NY-ESO-1157-170 in Combination with IFA Evokes a
Strong CD4 ؉ T Cell Response. Induction of specific CD4 ϩ T cells was analyzed by IFN-␥ enzyme-linked immunospot (ELISPOT) and intracellular staining after a single in vitro stimulation with ESO 157-170 . Patients 1 and 3 had preexisting peptide-reactive CD4 ϩ T cells, and patient 3 was also baseline seropositive for NY-ESO-1 (SI Table 3 ). In both patients, the frequency of peptide reactive CD4 ϩ T cells increased during the course of immunization. Of the remaining 16 patients, 13 demonstrated detectable ESO 157-170 -reactive CD4 ϩ T cells during the course of immunization (SI Table 3 ). The data indicate that ESO 157-170 -reactive CD4 ϩ T cells could be detectable by IFN-␥ ELISPOT as early as the third (day 43) vaccination in the majority of patients. As shown in Fig. 2A , there was a significant relationship between the number of vaccines and the maximal number of detectable ESO 157-170 -reactive CD4 ϩ T cells (Kendall's ; P ϭ 0.003). In the example shown, patient 18 completed all 15 vaccinations, and ESO 157-170 -reactive CD4 ϩ T cells were detected by IFN-␥ intracellular staining (ICS) (Fig. 2B ) and confirmed by IFN-␥ ELISPOT (SI Fig. 7) . Together, the data show that the proportion of patients with CD4
ϩ T cell response at the end of the study (83%) was significantly greater than the proportion at the start of therapy (11%) (McNemar's test; P ϭ 0.0009).
CD4 ؉ T Cells Induced by Vaccination with NY-ESO-1157-170 in Combi-
nation with IFA Recognize Tumor Targets. We previously showed that peptide vaccine-induced, NY-ESO-1 157-170 -specific CD4 ϩ T helper 1 (Th1) cells had limited capacity in recognizing naturally processed NY-ESO-1 protein in two patients using IFN-␥ ELISPOT (7) . We extended this analysis to functional tumor recognition by vaccineinduced NY-ESO-1 157-170 -specific CD4 ϩ T cells in additional patients. The results showed that NY-ESO-1 157-170 -specific CD4 ϩ T cells induced by immunization were able to recognize tumor targets more by production of IFN-␥ than TNF-␣. In the example shown in Fig. 3 for patient 18, vaccine-induced polyclonal NY-ESO-1 157-170-specific CD4 ϩ T cells were able to recognize DP4 ϩ ESO 
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End of study 6 mo. 9 mo. 12 mo. Fig. 1 . NY-ESO-1 serum Ab was assessed by ELISA before and after vaccination. Two baseline seronegative patients (10 and 13) converted to seropositive during the course of immunization. SK-Mel-37 tumor line, but not DP4 ϩ ESO Ϫ SK-Mel-23 tumor line (Fig. 3A) . To confirm this observation, ESO 157-170 -reactive CD4 ϩ T cells were sorted by using IFN-␥ capture and cloned by limiting dilution. We identified four clones that showed ESO 157-170 -specific response by using a peptide-pulsed, target antigen-presenting cell (T-APC). ESO 157-165 -specific CD8 ϩ CTLs and ESO 157-170 -specific CD4 ϩ T cells obtained from patient 18. For CD8 ϩ T cell clones, we found identical usage of V␤ and J␤, consistent with similarities in peptide avidity and tumor recognition ( Table 1 ). All clones also had identical CDR3 lengths and sequences. In contrast, there was functional clustering of TCR usage by CD4 ϩ T cells based on tumor-recognition properties. Although TCR usage by non-tumorreactive clones (including the two clones with higher peptide avidity than 5-B-8; i.e., 2-C-10 and 3-B-5) was identical (V␤6.1 and J␤2.5), clone 5-B-8 (able to recognize NY-ESO-1-expressing tumor cells) used V␤6.7 and J␤6.7 with different CDR3 lengths and sequences (Table 1) . These results show that although peptide avidity is an important determinant of tumor recognition by vaccine-elicited effector cells, TCR structural diversity also is critical for effector function.
Characterization of Long-Lived NY-ESO-1-Specific CD8 ؉ and CD4 ؉ T Cell Responses. To determine the longevity of vaccine-induced, NY-ESO-1-specific CD8 ϩ and CD4 ϩ T cell responses, peripheral mononuclear cells were obtained from patients without evidence of disease for at least 6 months after completion of vaccination. We observed detectable NY-ESO-1-specific CD4 ϩ T cells in all patients tested at 6 and 12 months. To address the possibility that the observed response might not be related to ESO 157-170 peptide vaccination, the results were confirmed by presensitizing CD4 ϩ T cells with a pool of 17 peptides, 20-mer in length, overlapping with 10 aa, and covering the full length of the NY-ESO-1 protein (data not shown). As illustrated in Fig. 6A Fig. 12) . Moreover, the A2/ESO 157-165 multimer-reactive cells also recognized ESO ϩ A2 ϩ melanoma cells SK-Mel-37 and MZ-Mel-19 by IFN-␥ ICS and CD107 (Fig. 6B) . For patient 18, although A2/ESO 157-165 multimer-reactive CD8 ϩ cells were detectable 6 months after the last immunization, at 13 months, the cells were no longer detectable (SI Fig. 13 ), suggesting that vaccine-elicited CD8 ϩ T cells persisted for at least 6 months but Ͻ1 year.
Clinical Results. The median time to disease progression/recurrence from start of vaccination was 19.0 months (Kaplan-Meier 95% confidence interval: 9.0 months3ϱ). Although a Cox proportional hazards model with a time-varying covariate indicated the number of vaccines to be significantly related to disease-free survival (log rank, one-sided test; P ϭ 0.035), this relationship could also be due to the reduced number of vaccines in patients with progressing disease. In one patient (patient 2) with measurable disease at enrollment, there was complete regression of metastatic disease after 10 immunizations (SI Fig. 14 A and B) . This response correlated with induction of CD4 ϩ and CD8 ϩ T cell responses (SI Table 3 and SI Fig. 11) . However, the patient developed recurrence of disease 8 months after discontinuation of vaccine. The patient did not receive cytotoxic chemotherapy during these intervening 8 months. She underwent secondary tumor-reductive surgery, followed by additional chemotherapy. Although the patient had detectable functional NY-ESO-1-specific CD8 ϩ and CD4 ϩ T cells 6 months after vaccination ( Fig. 6 and SI Fig. 12 ) (i.e., 2 months before detectable recurrence) and the recurrent tumor was more highly infiltrated by CD8 ϩ and CD4 ϩ T cells compared with the primary tumor (SI Fig. 14 C and D) , expression of NY-ESO-1 was no longer detectable by RT-PCR or immunohistochemistry (SI Fig.  14 E and F) , suggesting antigenic loss as a possible mechanism of immune evasion in the patient. 
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Discussion
During the past decade, remarkable progress has been made in understanding the interactions between the immune system and cancer. Importantly, evidence from correlative studies indicates that the presence of tumor-infiltrating lymphocytes may be associated with improved clinical outcome in several human cancers, including EOC (1, 8) . In the first human study of NY-ESO-1 vaccination, ESO 157-165 peptide in conjunction with granulocyte/ macrophage colony-stimulating factor was shown to induce HLA-A2-restricted CD8 ϩ T cell responses in patients without preexisting NY-ESO-1 immunity (9), although these peptide-induced CD8 ϩ T cell responses were generally of low affinity and did not recognize naturally processed NY-ESO-1 (10). Subsequently, recombinant NY-ESO-1 protein in a saponin-based adjuvant (ISCOMATRIX) was used to immunize stages III and IV melanoma patients after tumor resection (11) . More recently, patients with a range of tumor types were immunized with recombinant vaccinia NY-ESO-1 and recombinant fowlpox NY-ESO-1 (12) . These vaccine strategies induced high-titered NY-ESO-1 Ab, CD4 ϩ , and CD8 ϩ T cell responses in a high proportion of patients. Nonetheless, because of their ease of production, peptide vaccines remain attractive candidates for clinical use. In the current study, we have chosen an NY-ESO-1-derived peptide with dual HLA class I and II specificities, in combination with IFA to immunize a homogenous population of patients with ovarian cancer.
Our results indicate that vaccination with NY-ESO-1 157-170 induced integrated Ab, CD4 ϩ , and CD8 ϩ T cell responses in ovarian cancer patients (SI Table 4 ). The frequency of seroconversion that we observed is lower than that achieved with immunization with NY-ESO-1 protein/ISCOMATRIX (11) and recombinant vaccinia/fowlpox NY-ESO-1 (12) vaccines. One possible explanation for the lower frequency of B cell responses in our study is the relatively short length (14-mer) of the immunogen used compared with the full-length NY-ESO-1 used in the previous studies. Moreover, recent studies attempting to map B cell epitopes from spontaneous or full-length NY-ESO-1 vaccine-induced responses have demonstrated more frequent Ab responses to the N-terminal half compared with the C-terminal half of NY-ESO-1 (13), the location of the immunogen in the present study. Although induction of Ab response may be desirable for promoting T cell responses by in vivo cross-priming (14) , there are reports indicating that T cell responses may be skewed to Th1 type in the absence of B cell responses in some systems (15) . In this regard, our major objective of inducing tumor-reactive CD4 ϩ and CD8 ϩ T responses with this 14-mer peptide was achieved.
Based on our previous observations that direct ex vivo detection of NY-ESO-1-specific CD4 ϩ and CD8 ϩ T cells in peripheral blood is rare (even in patients with preexisting immunity to NY-ESO-1), we developed and optimized methods for amplifying NY-ESO-1-specific CD4 ϩ and CD8 ϩ T cell responses to include an in vitro stimulation step (16, 17) . The absence of detectable NY-ESO-1-specific T cells in healthy donors and the short in vitro stimulation step strongly suggest that NY-ESO-1-specific T cells in vaccinated patients have been primed in vivo. Our analyses indicate that the majority of patients developed detectable ESO 157-170 -reactive CD4 ϩ T cells. In contrast, only 4 of 14 (29%) patients developed class II-restricted reactivity to a related HLA-DP4-restricted epitope, ESO [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] , in a study by Khong et al. (18) . Although this result may be related to the differential ability of the peptides to induce class II-restricted immune responses, only two vaccinations were administered to the majority of patients in the study by Khong et al. (18) . Our finding indicating a significant relationship between higher number of vaccinations and the maximal number of detectable ESO 157-170 -reactive CD4 ϩ T cells supports the notion that peptide vaccination may require prolonged administration to demonstrate efficacy.
A relevant finding in this study is the demonstration of tumor recognition by vaccine-elicited CD8 ϩ and CD4 ϩ T cells. For CD8 ϩ T cells, previous clinical studies suggest that peptide vaccination with ESO 157-165 and ESO 157-167 generated NY-ESO-1-specific T cells that recognized peptides but not tumors (18, 19) . Moreover, vaccination with ESO 157-167 elicited CD8 ϩ T cell responses against a cryptic HLA-A2 epitope (amino acids 159-167) that were not tumor-reactive (19, 20) . Although we used a 14-mer peptide that included the cryptic NY-ESO-1 epitope, we have previously shown that the processing of longer peptides requires internalization and the action of the proteasome (21) . Thus, the requirement for trimming 3 aa from the C terminus of ESO 157-170 could explain why we did not observe generation of T cells against the cryptic epitope in the current study. Because we consistently observed induction of CD4 ϩ T cells in the majority of patients, we propose that simultaneous induction of NY-ESO-1-specific CD4 ϩ T cells might have enhanced the effector function of vaccine-elicited CD8 ϩ T cells. In support of this hypothesis, vaccine-elicited CD4 ϩ T cells also demonstrated a predominant Th1 cytokine profile that could enhance the quality of CD8 ϩ T cells. In this regard, cognate CD4 ϩ Th1 cells could provide IL-2 to CD8 ϩ T cells (22) and promote induction of CD8 ϩ T cell responses through dendritic cell activation by CD40-CD40L interactions (23) . Because our in vitro stimulation method for detecting NY-ESO-1-specific CD4 ϩ and CD8 ϩ T cells does not directly detect circulating precursor cells but rather cells proliferating in response to a cognate NY-ESO-1 epitope in vitro, the demonstration of tumor recognition is suggestive of the potential for recall responses and in vivo antitumor efficacy.
To gain insight into the structural basis of the functional differences between CTLs elicited from previous ESO 157-165 (ESO1b) peptide vaccine trials and the current study, we analyzed the TCR repertoire from one patient. Although TCR BV4.1 was dominant in previous ESO 157-165 (ESO1b) peptide vaccine trials (10), we found BV1 to be dominant in the current study and a striking homology of the CDR-3 regions of CTL clones that highly correlated to similar functional characteristics, such as tumor recognition and cytokine production. Although it is possible that differences in TCR usage could be shaped by host factors, such as allelic polymorphism in TCR gene segments (24) or recognition of autologous peptides by thymocytes in a different HLA context during negative selection in the thymus (25) , our findings suggest that simultaneous induction of CD4 ϩ T cells by ESO 157-170 vaccination may be associated with recruitment of a functionally distinct repertoire of CD8 ϩ T cells with enhanced tumor-recognizing properties. The generation of functional memory T cells is one of the major goals of cancer vaccines. In our study, we detected long-lived functional ESO 157-170 -specific CD4 ϩ T cells and ESO 157-165 CD8 ϩ T cells 6 months after completion of immunizations in all patients and at 12 months in some patients. Although longevity of immune responses was not addressed in previous NY-ESO-1 peptide vaccine studies (9, 18, 19) , sustenance of vaccine-induced responses might also be related to the dual MHC class I and II specificities of the peptide vaccine in the current study. Importantly, it has been reported that CD4 ϩ Th cells are required in determining the magnitude and persistence of CTL responses (26) . Although our study was designed as a phase 1 clinical trial, we noted encouraging clinical results. Considering that almost half of the study population consisted of patients who received between two and eight previous lines of chemotherapy for ovarian cancer, the finding of median progression-free survival of 19.0 months was striking. In general, after completion of front-line treatment for recurrent disease, EOC patients have progressively shorter and predictable progression-free intervals. Thus, progression-free survival after first-line i.v. platinum-based chemotherapy is Ϸ18 months (27) and is reduced significantly to 16-18 weeks in patients receiving second-line chemotherapy (28) . Nevertheless, because a significant proportion of patients in our study still developed progression/recurrence of disease, we question the potential mechanisms of immune escape in the ovarian cancer population. We previously showed that the beneficial prognostic effect of CD8 ϩ tumor-infiltrating lymphocytes in ovarian cancer patients is adversely affected by CD4 ϩ CD25 ϩ FOXP3 ϩ regulatory T cells (Tregs) with immunosuppressive properties (1). Although we did not observe any significant expansion of Tregs by vaccination in the current study (data not shown), we previously showed that vaccination with an ESO 157-170 peptide failed to modulate the suppressive effect of Tregs on high-avidity NY-ESO-1-specific T cell precursors (7). In the current report, we found lack of NY-ESO-1 expression in recurrent tumors in a subset of patients, suggesting antigen loss as a potential mechanism of immune escape. Together the findings from our previous (1, 7) and current studies argue for future development of a multimodal immunization strategy in EOC to (i) actively counteract the effects of Tregs, (ii) minimize tumor antigen loss through epigenetic modulation, and (iii) incorporate multiple antigenic targets containing CD8 ϩ and CD4 ϩ T cell epitopes in the vaccine constructs. ESO-or LAGE-1-expressing EOC or primary peritoneal carcinoma, stages II-IV at diagnosis. Expression of NY-ESO-1 and/or LAGE-1 was detected in tumors by RT-PCR and/or immunohistochemistry as described (3) . The NY-ESO-1 peptide sequence for immunization was ESO 157-170 (SLLMWITQCFLPVF). The vaccine was composed of 100 g of ESO 157-170 and 500 l of IFA and was injected s.c. once every 3 weeks. In the absence of toxicity and disease progression that required other therapeutic interventions, patients received up 15 injections.
Materials and Methods
NY-ESO-1 Serum Ab. NY-ESO-1-specific Abs were measured in the serum by ELISA on the day of each vaccination and at 6 and 12 months after the last vaccination as described (3).
Analysis of NY-ESO-1-Specific T Cells. For the analysis of CD8 ϩ T cells, ESO 157-170 and a pool of synthetic overlapping 18-to 20-mer NY-ESO-1 peptides covering the entire NY-ESO-1-protein sequence were used for in vitro stimulation. ESO 157-165 and ESO 158-168 peptides also were used for in vitro stimulation in HLA-A2 and HLA-A24 patients, respectively. In all patients, purified CD4 ϩ T cells were stimulated with DP4 peptide (ESO 157-170 ). Presensitized CD8 ϩ T cells were stained with phycoerythrin-labeled HLA-A2 or HLA-A24 multimers as previously described (16) . Presensitized CD4 ϩ T cells were tested for intracellular IFN-␥ secretion; CD8 ϩ T cells were tested for IFN-␥ and CD107a/b expression against target cells as previously described. All mAbs were obtained from BD PharMingen (San Diego, CA).
ELISPOT Assay. Presensitized CD8 ϩ or CD4 ϩ T cells were assessed by ELISPOT as described (17) . A response was considered positive when spot numbers in triplicate assays in the presence of target cells significantly exceeded the cutoff value, corresponding to the number of nonspecific spots in the presence of flu-NP (for CD4 ϩ cells) or flu-HA (for CD8ϩ cells) peptide loaded on target cells (cutoff was mean Ϯ 3 SD). A detailed description of cell lines, assay for tumor recognition, and molecular TCR repertoire analysis is available in SI Materials and Methods. 
